Best Momentum Stocks to Buy for July 3rd
https://www.zacks.com/commentary/2296424/best-momentum-stocks-to-buy-for-july-3rd?cid=CS-ZC-FT-zacks_1_rank_additions|momentum_additions-2296424
Jul 03, 2024 - SRPT and ASYS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 3, 2024.
0
New Strong Buy Stocks for July 3rd
https://www.zacks.com/commentary/2295884/new-strong-buy-stocks-for-july-3rd?cid=CS-ZC-FT-zacks_1_rank_additions-2295884
Jul 03, 2024 - MONDY, MWA, SRPT, ASYS and CLCO have been added to the Zacks Rank #1 (Strong Buy) List on July 3, 2024.
0
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
https://www.zacks.com/stock/news/2294577/biotech-stock-roundup-alny-up-on-study-success-alim-on-merger-news-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2294577
Jun 27, 2024 - Alnylam Pharmaceuticals (ALNY) and Alimera Sciences, Inc. (ALIM) are in the spotlight following study and merger updates, respectively.
0
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
https://www.zacks.com/stock/news/2291689/fda-expands-sarepta-s-srpt-dmd-gene-therapy-label?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2291689
Jun 21, 2024 - Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.
0
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
https://www.zacks.com/stock/news/2287702/pfizer-pfe-phase-iii-dmd-gene-therapy-study-misses-goal?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2287702
Jun 13, 2024 - Pfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory boys with DMD treated with its gene therapy fordadistrogene movaparvovec compared to placebo.
0
Implied Volatility Surging for Sarepta (SRPT) Stock Options
https://www.zacks.com/stock/news/2278837/implied-volatility-surging-for-sarepta-srpt-stock-options?cid=CS-ZC-FT-tale_of_the_tape|options-2278837
May 24, 2024 - Investors need to pay close attention to Sarepta (SRPT) stock based on the movements in the options market lately.
0
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
https://www.zacks.com/stock/news/2276830/dyne-dyn-soars-28-on-new-data-from-muscle-disease-studies?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2276830
May 21, 2024 - Dyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage studies evaluating DYNE-101 and DYNE-251 for different muscle disease indications.
0
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
https://www.zacks.com/stock/news/2267221/sarepta-srpt-q1-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2267221
May 02, 2024 - Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
0
Sarepta Therapeutics (SRPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
https://www.zacks.com/stock/news/2266535/sarepta-therapeutics-srpt-q1-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2266535
May 01, 2024 - Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
0
Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/05/01/sarepta-therapeutics-srpt-q1-2024-earnings-call-tr/?source=iedfolrf0000001
May 01, 2024 - SRPT earnings call for the period ending March 31, 2024.
0